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To deliver high doses of radiation to tumours by radiolabelled antibodies it is necessary to achieve high levels of incorporation of the label. Most methods of radioiodination of antibodies can be adapted to do this. However, operators can receive unacceptably high doses of radiation, less from the iodination itself than from subsequent purification by gel filtration to separate the iodinated protein from free iodine. It is extremely difficult to carry out gel filtration with adequate lead shielding, and clearing up highly contaminated waste is another area of possible radiation exposure. This communication describes a modification to the method of Mather and Ward! for the labelling of antibodies using N-bromosuccinimide. Labelling efficiencies of about 90% were obtained, no further purification was required and minimal contaminated waste was produced. The labelled antibody appeared to localise well and radiation doses to staff were very low.
Materials and methods
A monoclonal antibody A5B7 to carcinoembryonic antigen (CEA) and two monoclonal antibodies WI4 and SBIO to human chorionic gonadotrophin (HCG) were labelled. The antibodies were heat treated at 56°C for 30 min and the pH was adjusted to 7·4 prior to concentration to 10-15 mg in~0'5 mL in a Minicon Concentrator (Amicon Ltd, Stonehouse, Glos, UK). The following three reagents were prepared: a I mol/L phosphate buffer in sterile water at pH 7-4 which was then autoclaved, a 1 mg/ml, solution of Nbromosuccinimide (Sigma Chemical Co Ltd, Poole, Dorset, UK) in sterile water, and a 2 mg/ mL solution of L-tyrosine (BDH Chemicals Ltd, Poole, Dorset, UK) in sterile water. These three reagents were filtered through 0·22 Jlm filters and the required amounts drawn up into disposable 244 syringes in an air-flow cabinet. The antibody was also drawn up into a disposable syringe in the same cabinet. These loaded syringes were then transferred to an enclosed labelling cabinet together with 50 mCi of Jl31 in 250 JlL of dilute NaOH in its lead pot (Amersham International pic, Aylesbury, Bucks, UK). The radioisotope in its lead pot was surrounded by a further wall of lead bricks and the cabinet was then sealed. The top of the lead pot was removed and all subsequent operations were carried out using forceps. After wiping the rubber septum of the labelling vial with a 'Steret' swab, a 'bleed' needle was inserted. First, 100 JlL of I mol/L phosphate buffer was added, followed by 10-15 mg of antibody in~0'5 mL. Then 70 JlL ofN-bromosuccinimide solution was added and the mixture gently shaken for 45 s. Finally, 100 JlL of the Ltyrosine solution was added to stop the reaction. All the reagents were added through a single needle and no further purification or separation was involved.
In order to assess the iodination procedure quantitatively and to check for any damage to the antibody by the labelling, an aliquot of 50 JlL was removed and diluted to I mL with sterile water. This together with the labelling took approximately 4 min. The top of the lead pot was then replaced.
The diluted labelled antibody was then used to measure the labelling efficiency, by instant thin layer chromatography (lTLC) using Merck HPTLC aluminium sheets pre-coated with silica gel 60 F254 (BDH Ltd, Poole, Dorset, UK). The mobile phase was 80 % methanol. Autoradiography was carried out to give visual evidence of separation of the iodinated protein and the free iodine prior to the chromatography strip being cut up and the activity measured in an ionisation chamber. The diluted antibody was run on a fast protein liquid chromatography (FPLC) system (LKB/Pharmacia, Milton Keynes, Bucks, UK) and the trace compared with that of the preiodinated antibody. The same diluted antibody was checked for immunogenicity by comparing its anti-serum dilution curve with that of the uniodinated antibody, using a radioimmunoassay technique.
Operators wore whole body thermoluminescent dosimetry monitors throughout the procedure.
Results
Labelling efficiences in the range 88-94% were consistently achieved as demonstrated by ITLC. The single peak shown on the post-iodination trace on FPLC was identical with that of the preiodination trace, indicating the absence of aggregates due to labelling. The anti-serum dilution curves for the unlabelled and the labelled anti-CEA MoAb 4 days post-iodination could be superimposed within the limits of experimental error, which suggests good retention of immunogenicity.
Radioiodination for therapy 245 Figure I shows localisation, by a posterior area-scan, of the anti-CEA MoAb in the liver metastases of a patient 51 h after administration of labelled antibody. This is a typical scan following the administration of labelled antibody.
The radiation doses to the operator measured by a whole body dosemeter ranged from 9 to 22 IlSv.
Discussion
The mild oxidising reagent N-bromosuccinmide can be used to iodinate tyrosine-containing proteins.! Since the method is very quick, little or no damage to the protein results. This is confirmed by the absence of changes in the post-iodination FPLC trace when compared with the pre-iodination trace.
The addition of L-tyrosine to stop the reaction may account for the good retention of immunogenicity at 4 days post-iodination. In practice, the antibody is usually administered to the patient immediately after iodination. Since no separation step takes place a small amount of L-tyrosine and N-bromosuccinimide are given to the patient. L-Tyrosine is not known to be harmful to humans, and the dose ofN-bromosuccinimide is 1/250000 of the dose that has been shown to give toxic effects in mice [Registry of Toxic Effects of Chemical Substances (RTECS 1981-82) ]. Good localisation by the radiolabelled antibody was seen for both anti-HCG and anti-CEA.
Because of the simplicity of the procedure, which is carried out in the iodine vial contained in its lead pot with additional simple shielding, exposure of the operator to radiation is very low. The whole reaction requires the top of the lead pot to be removed for only 4 min, and the amount of contaminated waste is minimal. The radiation dose to the operator is in the region of 20 IlSV so that therapeutic labelling can be carried out in most conventional hospital laboratories possessing an air-flow cabinet capable of being sealed.
